Metachronous immune-related adverse events involving type 1 diabetes and isolated adrenocorticotropic hormone deficiency associated with pembrolizumab monotherapy for metastatic head and neck cancer: a case report

Table 1 Blood parameters tested on day 252

Blood cell count		Biochemistry		Urine analysis		Venous blood gas
WBC	11,100/μℓ	Alb	4.0 g/dl	Protein	±	pH	7.237
RBC	344 104/μℓ	CK	75I U/L	Glucose	4 +	PCO2	30.7
Hb	11.8 g/dℓ	AST	18 IU/L	Specific gravity	1.031	PO2	101.0
Ht	36.3%	ALT	15 IU/L	pH	5.5	HCO3-	12.6
MCV	105.5 fl	LDH	204 IU/L	Urobilinogen	normal	Anion Gap	28.4
PLT	23.0 104/μℓ	ALP	58 IU/L	Bilirubin	(−)
		Cr	0.60 mg/dl	Ketone body	3 +
		BUN	28 mg/dl	Leukocytes	(−)
		Glu	407 mg/dl	Nitrous acid	(−)
		Na	136 mEq/L	Occult blood	(−)
		K	5.2 mEq/L
		Cl	97 mEq/L
		CRP	5.337 mg/dl
		HbA1c	6.6%

WBC white blood cells, RBC red blood cells, Hb hemoglobin, Ht hematocrit, MCV mean corpuscular volume, PLT platelets, Alb albumin, CK creatine kinase, AST aspartate transferase, ALT alanine transaminase, LDH lactate dehydrogenase, ALP alkaline phosphatase, Cr creatinine, BUN blood urea nitrogen, CRP c-reactive protein

ISSN: 1752-1947